Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + cyclophosphamide + allogeneic peripheral blood stem cells
- Development stage
- Unknown
- Lead developer
- Cancer and Leukemia Group B
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
This therapeutic regimen consists of a non-myeloablative (reduced-intensity) conditioning phase using the chemotherapy agents fludarabine and cyclophosphamide, followed by an allogeneic peripheral blood stem cell (PBSC) transplant. Fludarabine and cyclophosphamide serve to lymphodeplete the patient, preventing graft rejection and providing some anti-tumor activity. The subsequent infusion of donor PBSCs (containing CD34+ hematopoietic stem cells and CD3+ T-lymphocytes) aims to establish a new hematopoietic system and induce a graft-versus-leukemia (GVL) effect, where donor immune cells recognize and eliminate residual malignant cells. This approach is specifically investigated for patients with chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), low-grade non-Hodgkin lymphoma (NHL), and mantle cell lymphoma (MCL).
- Other names
- Minimal Ablation Allo-SCTfludarabine + cyclophosphamide + PBSCMinimal Ablation and Cellular Immune Therapy
02
Targets
DNA polymerase familyDNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on fludarabine + cyclophosphamide + allogeneic peripheral blood stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + cyclophosphamide + allogeneic peripheral blood stem cells.